In January 2021, Edison Oncology and Apollomics entered into a licensing agreement under which Apollomics has been granted worldwide rights, excluding China, Hong Kong and Taiwan, for the development and commercialization of EO1001. EO1001 is a protein tyrosine kinase inhibitor (TKI) that has demonstrated irreversible inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent.

Under the terms of the agreement, Edison Oncology has received an upfront cash payment and is eligible to receive potential development and sales milestone payments, as well as tiered royalties on net sales. Apollomics will be responsible for all costs related to development, regulatory approvals, and commercialization activities for EO1001 in the territories.

Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several development-stage assets, including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visit http://www.apollomicsinc.com.

Apollomics USA is headquartered in Foster City, CA.

In March 2021, Edison Oncology transferred rights to three series of novel DNA-damage response (DDR) inhibitors, including the EO2000 a series of Novel PARP-inhibitors, to Rakovina Therapeutics, Inc. (TSX-V: RKV). Edison Oncology currently holds approximately 43% of the issued and outstanding common shares of Rakovina Therapeutics.

Rakovina Therapeutics’ focus is the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. For more information, please visit http://www.rakovinatherapeutics.com.

Rakovina Therapeutics is headquartered in Vancouver, Canada.